Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bradley Tenny

Nurse Practitioner Charlotte, NC Nurse Practitioner

NPI 1437690237 CMS profile 10879294

1021 Morehead Medical Dr Ste 6100, Ste 6100, Charlotte, NC 28204

Open in the dashboard

General payments

$1,303

13 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradley Tenny of Charlotte, NC is reported in the CMS Open Payments database as having received $1,303 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36 1
2024 General $43 2
2023 General $1,081 8
2022 General $85 1
2021 General $57 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Tenny
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Bradley Tenny were reported at $36. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Bradley Tenny Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $57 $135 $40–$426 $132
2022 $85 $152 $48–$470 $149
2023 $1,081 $166 $54–$529 $160
2024 $43 $173 $55–$556 $164
2025 $36 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Endo Pharmaceuticals Inc. $946 3 payments
  2. Urogen Pharma, Inc. $215 8 payments
  3. Boston Scientific Corporation $142 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $673 12 payments
  2. Consulting Fee $630 1 payment
Products named General payments · program years 2021–2025
  1. XIAFLEX $946 3 payments
  2. JELMYTO $179 7 payments
  3. LithoVue LithoVue_URO $85 1 payment
  4. LITHOVUE Pain Management $57 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

442

Median for Nurse Practitioner: 389

Drug cost

$27,412

Median for Nurse Practitioner: $21,885

Branded share of claims

12.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 29 $20,751
Tamsulosin Hcl Generic 182 $2,614
Solifenacin Succinate Generic 48 $1,373
Trospium Chloride Generic 23 $1,088
Finasteride Generic 76 $1,015
Ciprofloxacin Hcl Generic 29 $168
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 12 $147
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 13 $144
Cephalexin Generic 30 $112

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$30,352

Medicare's payments for the services billed

Medicare patients

339

Average age 74

Services billed

777

22 women, 317 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 71%
Chronic kidney disease 30%
Arthritis 30%
Ischemic heart disease 29%
Diabetes 27%
Atrial fibrillation 17%
Depression 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JELMYTO
  • UROGEN PHARMA, INC. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record